S

Shandong Boan Biotechnology Co Ltd
HKEX:6955

Watchlist Manager
Shandong Boan Biotechnology Co Ltd
HKEX:6955
Watchlist
Price: 8.86 HKD 0.91% Market Closed
Market Cap: 4.7B HKD
Have any thoughts about
Shandong Boan Biotechnology Co Ltd?
Write Note

Shandong Boan Biotechnology Co Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shandong Boan Biotechnology Co Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
S
Shandong Boan Biotechnology Co Ltd
HKEX:6955
Total Receivables
ÂĄ293.1m
CAGR 3-Years
112%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Receivables
ÂĄ3.2B
CAGR 3-Years
77%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Receivables
ÂĄ1.4B
CAGR 3-Years
11%
CAGR 5-Years
48%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Receivables
ÂĄ3.1B
CAGR 3-Years
62%
CAGR 5-Years
72%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Receivables
ÂĄ25.5B
CAGR 3-Years
34%
CAGR 5-Years
41%
CAGR 10-Years
46%
Imeik Technology Development Co Ltd
SZSE:300896
Total Receivables
ÂĄ230.8m
CAGR 3-Years
72%
CAGR 5-Years
75%
CAGR 10-Years
N/A
No Stocks Found

Shandong Boan Biotechnology Co Ltd
Glance View

Market Cap
4.5B HKD
Industry
Biotechnology

Shandong Boan Biotechnology Co., Ltd. operates as a biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization. The company is headquartered in Yantai, Shandong and currently employs 631 full-time employees. The company went IPO on 2022-12-30. The firm is engaged in the development, production and commercialisation of therapeutic antibodies, focusing on the therapeutic areas of oncology, metabolism, autoimmunology and ophthalmology. The firm has three main technology platforms: a fully human antibody transgenic mouse and phage display technology platform, a bispecific T-cell Engager technology platform, and an antibody drug coupling (ADC) technology platform. The firm operates mainly in the domestic Chinese market and overseas markets.

Intrinsic Value
12.74 HKD
Undervaluation 30%
Intrinsic Value
Price
S

See Also

What is Shandong Boan Biotechnology Co Ltd's Total Receivables?
Total Receivables
293.1m CNY

Based on the financial report for Dec 31, 2023, Shandong Boan Biotechnology Co Ltd's Total Receivables amounts to 293.1m CNY.

What is Shandong Boan Biotechnology Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 3Y
112%

Over the last year, the Total Receivables growth was 29%. The average annual Total Receivables growth rates for Shandong Boan Biotechnology Co Ltd have been 112% over the past three years .

Back to Top